Cellular pharmacology of 9-(β-D-1,3-dioxolan-4-yl) guanine and its lack of drug interactions with zidovudine in primary human lymphocytes

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 6, 2007, Pages 343-346

  Hernandez Santiago, Brenda I ^a   Obikhod, Aleksandr ^a   Fromentin, Emilie ^a   Hurwitz, Selwyn J ^a   Schinazi, Raymond F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular pharmacology; DXG; NRTI; Nucleoside analogues

Indexed keywords

9 (BETA DEXTRO 1,3 DIOXOLAN 4 YL)GUANINE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG; ZIDOVUDINE; 1,3 DIOXOLANE DERIVATIVE; 9 (1,3 DIOXOLAN 4 YL)GUANINE; 9-(1,3-DIOXOLAN-4-YL)GUANINE; DRUG DERIVATIVE; GUANINE; PRODRUG;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; HUMAN; HUMAN CELL; LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE; CELL CULTURE; DRUG EFFECT; DRUG INTERACTION; HALF LIFE TIME; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; MUTATION; PHOSPHORYLATION; VIROLOGY;

CELLS, CULTURED; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GUANINE; HALF-LIFE; HIV; HUMANS; LYMPHOCYTES; MUTATION; PHOSPHORYLATION; PRODRUGS; ZIDOVUDINE;

EID: 41349096516     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800606     Document Type: Article

References (6)

1. Bazmi H, Hammond JL, Cavalcanti SC, Chu CK, Schinazi RF & Mellors JW (2000) In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′deoxythymidine. Antimicrobial Agents Chemotherapy 44:1783-1788.
2. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P & Locarnini S (2001) In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrobial Agents Chemotherapy 45: 2495-2501.
3. Gu Z, Wainberg Ma, Nguyen-Ba N, L'Heureux L, De Muys JM, Bowlin TL & Rando RF (1999) Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrobial Agents Chemotherapy 43:2376-2382.
4. Mewshaw JP, Myrick FT, Wakefield DA, Hooper BJ, Harris JL, McCreedy B & Borroto-Esoda K (2002) Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. Journal of Acquired Immune Deficiency Syndromes 29:11-20.
5. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C & Zoulim F (2002) Inhibitory activity of dioxolane purine analogues on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36:710-722.
6. Ying C, De Clercq E, Nicholson W, Furman P & Neyts J (2000) Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. Journal of Viral Hepatitis 7:161-165.